64 related articles for article (PubMed ID: 38688599)
1. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Moffat GT; Kong W; MacKay HJ; McGee J; Booth CM; Ethier JL
Gynecol Oncol; 2024 May; 184():51-56. PubMed ID: 38281412
[TBL] [Abstract][Full Text] [Related]
2. Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis.
Leung JH; Leung HWC; Wang SY; Yip Fion HT; Chan ALF
Medicine (Baltimore); 2024 May; 103(21):e38183. PubMed ID: 38788019
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G; Floquet A; Tredan O; Carrot A; Langlois-Jacques C; Lopez J; Selle F; Abdeddaim C; Leary A; Dubot-Poitelon C; Fabbro M; Gladieff L; Lamuraglia M
Nat Commun; 2024 Mar; 15(1):1985. PubMed ID: 38443333
[TBL] [Abstract][Full Text] [Related]
4. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M
Gynecol Oncol; 2024 Jun; 185():128-137. PubMed ID: 38412736
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer.
Kochi Y; Hosoya S; Yanaihara N; Nagata C; Honda R; Shimazaki M; Yokosu K; Kuroda T; Saito M; Tanabe H; Yamada K; Takano H; Okamoto A
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38865025
[TBL] [Abstract][Full Text] [Related]
6. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.
Harutyunyan L; Manvelyan E; Karapetyan N; Bardakhchyan S; Jilavyan A; Tamamyan G; Avagyan A; Safaryan L; Zohrabyan D; Movsisyan N; Avinyan A; Galoyan A; Sargsyan M; Harutyunyan M; Nersoyan H; Stepanyan A; Galstyan A; Danielyan S; Muradyan A; Jilavyan G
Curr Oncol; 2024 Mar; 31(3):1323-1334. PubMed ID: 38534933
[TBL] [Abstract][Full Text] [Related]
7. OCEANIA: real-world study of ovarian cancer treatment patterns across multiple lines of therapy in Argentina and Brazil.
Soares C; Abreu G; Nogueira da Silva TL; Queiroz J; Menezes P; Bernardino G; Pires T; Carrizo M; Felice R; Riggi MC; Cravero F; Alves Ribeiro de Souza AL; Jotimliansky L
Future Oncol; 2024 May; ():1-14. PubMed ID: 38861309
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
10. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
12. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
14. Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
Fukuda T; Noda T; Uchikura E; Awazu Y; Tasaka R; Imai K; Yamauchi M; Ichimura T; Yasui T; Sumi T
Anticancer Res; 2023 Jul; 43(7):3097-3105. PubMed ID: 37351971
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
